Interpreting cancer biology: Refining our therapeutic algorithm in breast cancer

Oncologist

Volumn 18, Issue 4, 2013, Pages

  Hortobágyi, Gabriel ^a   Conte, Pierfranco ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN;

BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; COPY NUMBER VARIATION; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETIC ALGORITHM; HUMAN; NOTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 84877038637     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0117     Document Type: Note

References (19)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
3. Sorlie T, Perou C, TibshiraniRet al.Geneexpression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
4. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012 Jun 20;486(7403):405-9.
5. Mauri D, Pavlidis N, Polyzos NP et al. Survival with aromataseinhibitorsandinactivators versus standard hormonal therapy in advanced breast cancer: metaanalysis. J Natl Cancer Inst 2006;98:1285-91.
6. Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:435-44.
7. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013;309:800-5.
8. Colleoni M, Anders C. Is the biology of breast cancer in young women unique? The Oncologist 2013:18;e8-e10.
9. Iwamoto T, Bianchini G, Booser D et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011 Feb 2;103(3):264-72.
10. Dutta B, Pusztai L, Qi Y et al. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer 2012;106:1107-16.
11. Kelly C, Symmans FW, Andreopoulou E et al. Breast cancer genomics: challenges in interpretation and application. The Oncologist 2013;18:e11-e12.
12. Food and Drug Administration "Draft Guidance-In Vitro Companion Diagnostic Devices", July2011.
13. Food and Drug Administration. FY2011 Innovative Drug Approvals. Available online: http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm276385.htm (accessed on 21st March 2013).
14. European Medicines Agency. Qualification of novel methodologies for medicine development: Guidance to applicants. Available online: http://www.ema.europa.eu/ema/index.jsp?curl_pages/regulation/document_listing/document_listing_ 000319.jsp&mid_WC0b01ac0580022bb0 (accessed 21st March 2013).
15. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004 351: 2817-2826.
16. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 415: 530-536.
17. Ross JS, Hatzis C, SymmansWFet al. Commercialized multigene predictors of clinicaloutcomefor breast cancer. The Oncologist 2008;13:477-493.
18. http://www.hse.ie/eng/services/Find_a_Service/National_Cancer_Control_Programme/Oncotype%20DX%20to%20be%20made%20available%20in%20all%20designated%20cancer% 20centres.html (accessed on 21st March 2013).
19. National Institute for Health and Clinical Excellence. Diagnostics consultation document - Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. February 2013.